RVMD Revolution Medicines

Revolution Medicines to Participate in Upcoming Investor Conferences

Revolution Medicines to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will be a featured speaker at the 23rd Annual Needham Healthcare Conference and the Stifel Targeted Oncology Forum.

Details of the company’s participation are as follows:

  • 23rd Annual Needham Healthcare Conference

    Conference Dates: April 8-11, 2024

    Fireside Chat Time/Date: 1:30 – 2:10 p.m. ET on Thursday, April 11, 2024

    Location: Virtual; webcast available
  • Stifel Targeted Oncology Forum

    Conference Dates: April 16-17, 2024

    Fireside Chat Time/Date: 3:30 – 3:55 p.m. ET on Tuesday, April 16, 2024

    Location: Virtual; webcast available

To access the live webcasts of the Needham and Stifel fireside chats, please visit the “Events & Presentations” page of Revolution Medicines’ website at . Additionally, a replay of each webcast will be available on the “Events & Presentations” page of the Revolution Medicines website for at least 14 days following the conference.

About Revolution Medicines, Inc.

Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS companion inhibitors for use in combination treatment strategies. The company’s RAS(ON) inhibitors RMC-6236, a RAS(ON) multi-selective inhibitor, RMC-6291, a RAS(ON) G12C-selective inhibitor, and RMC-9805, a RAS(ON) G12D-selective inhibitor, are currently in clinical development. Additional RAS(ON) mutant-selective inhibitors in the company’s development pipeline include RMC-5127 (G12V), RMC-0708 (Q61H) and RMC-8839 (G13C).



Media & Investor Contact
Erin Graves
650-779-0136
 
EN
04/04/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Revolution Medicines

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Geoffrey Von Der Ahe ... (+3)
  • Geoffrey Von Der Ahe
  • Ritika Das
  • Robert Driscoll
 PRESS RELEASE

Revolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236) Under...

Revolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236) Under FDA Commissioner's National Priority Voucher Pilot Program REDWOOD CITY, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted a non-transferrable voucher for daraxonrasib (RMC-6236), the company’s RAS(ON) multi-selective inhibitor, under the Commissioner's National Priority Voucher (CNPV) pilot program. ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch